Credit Card Icon
Online bill pay
Calendar Icon
Book Now
Filed Paper Icon
patient portal
Doctor Icon
For Physicians
Phone Icon
(763) 416-7600

Understanding POAG Eye: Symptoms, Diagnosis, Treatments, and Costs

Posted by: Northwest Eye in poag eye on April 21, 2026

What POAG means

POAG means primary open-angle glaucoma. POAG is a chronic, progressive disease that damages the optic nerve and retinal nerve fiber layer while the eye’s drainage angle remains open. The disease usually affects both eyes, although damage can be worse in one eye.

POAG is the most common form of glaucoma in the United States. An estimate placed the number of people with POAG worldwide at 53 million in 2020, with a prevalence of 3.0% among people ages 40 to 80. The 3.0% figure describes the share of people in that age range, not your personal chance of having POAG.

In open-angle glaucoma, resistance in the eye’s drainage tissue can slow fluid drainage. Fluid can then build up, raise pressure inside the eye, and damage the optic nerve. The open angle means the drainage angle appears open even though resistance within the drainage tissue can still interfere with fluid movement.

Clinicians diagnose POAG by combining an optic-nerve examination, gonioscopy, visual-field testing, eye-pressure measurement, and central-corneal-thickness measurement. Eye pressure, symptoms, or family history can raise concern, but none of them establishes the condition by itself. An eye specialist combines optic-nerve findings, drainage-angle findings, visual-field results, and changes over time before deciding what the findings mean.

POAG can threaten vision if damage progresses, but early diagnosis and treatment can generally prevent visual disability. That is why a gradual or absent symptom pattern still deserves attention when risk factors or abnormal test results are present.

What can raise your risk

POAG risk factors include age, eye pressure, family history, diabetes, and certain health conditions. Reported risk factors include:

  • Older age.
  • African race or Latino or Hispanic ethnicity.
  • Elevated eye pressure.
  • A family history of glaucoma.
  • Type 2 diabetes.
  • A thin central cornea.
  • Low blood pressure or lower ocular perfusion pressure.
  • Hypothyroidism.
  • Obstructive sleep apnea.
  • Cardiovascular disease.
  • Nearsightedness, also called myopia.

A risk factor does not mean that you have POAG. Share these details during an eye examination so the clinician can interpret your findings in context.

People of African ancestry have a higher prevalence of POAG, may develop it earlier, and often have a more aggressive form than Caucasian populations. Population-level POAG patterns do not determine an individual examination result.

Eye pressure is one part of POAG risk, but eye pressure alone cannot settle the question. POAG is often linked with high eye pressure, but glaucoma can also occur when eye pressure is in the average range. A pressure reading is one measurement taken at one time, while the diagnosis depends on several findings and sometimes follow-up testing.

Tell your eye-care professional about glaucoma in your family and about conditions such as diabetes, sleep apnea, thyroid disease, or cardiovascular disease. Mention nearsightedness and any history of low blood pressure as well.

Some people have glaucoma-related optic-nerve damage even when eye pressure falls within the average range. Normal-pressure or low-tension glaucoma can involve this pattern. Lowering eye pressure can still reduce progression risk in normal-pressure or low-tension glaucoma.

Why you may not notice it

Early POAG usually causes few or no symptoms, so you may not notice vision changes until damage is more advanced. Glaucoma-related vision changes may develop gradually, and you may not notice them at first. One eye can compensate for the other, which can make a slow change harder to recognize. Early POAG may therefore remain unnoticed even while damage is developing. An examination can still be useful before you notice a change. The clinician uses the examination and, when needed, follow-up testing to interpret what is happening. This quiet pattern is one reason a person may need evaluation even without a clear change in everyday vision. Slow changes in one eye can be especially difficult to recognize when the other eye provides a clearer view.

Visual-field loss can eventually affect daily activities. Some people notice missing stairs, parts of words, or difficulty driving as visual-field loss develops. Glaucoma usually affects the edges of your vision first; if it is not treated, it can later affect central vision.

Advanced glaucoma may cause side-vision problems, difficulty seeing in bright light, or difficulty adjusting when moving between light and dark environments.

Awareness of glaucoma also varies. In one U.S. survey, 16% of African Americans surveyed said they were unfamiliar with glaucoma, while 30% of all Americans surveyed said they had never heard of it. Those percentages describe the surveyed groups and do not estimate the chance that any particular person has POAG.

Infographic showing reported glaucoma awareness survey results: 16% of African Americans surveyed were unfamiliar with glaucoma, while 30% of all Americans surveyed had never heard of it.
The survey results describe awareness in the groups studied, not an individual’s chance of having POAG.

What the eye examination checks

A POAG evaluation combines several parts of an eye examination. Clinicians assess the optic nerve, the drainage angle, the visual field, eye pressure, and central corneal thickness. The examination may include:

  • An optic-nerve examination.
  • Gonioscopy, which examines the angle where fluid drains from the eye.
  • Eye-pressure measurement.
  • Visual-field testing.
  • Measurement of central corneal thickness.
  • Scans or photographs of the optic nerve and retinal nerve fiber layer.

Clinicians may use OCT, which means optical coherence tomography, to assess the optic nerve and retinal nerve fiber layer. They may repeat tests over time to look for change. A single result may not explain the whole picture.

A POAG diagnosis can require monitoring over years because clinicians may need to document disease-related changes.

A visual-field test checks central and side vision while you look at a central light and signal when you see other lights. The test is painless and takes about 10 minutes per eye. It can show missing areas caused by optic-nerve damage.

A glaucoma examination may be painless, although dilating drops can temporarily blur your vision. The clinician may also examine the part of the eye involved in fluid drainage and inspect the visible part of the optic nerve.

The cited NHS description advises not driving to an appointment when dilating drops are used because the drops can temporarily blur vision. During gonioscopy, a clinician places a specialized contact lens on the numbed eye to view the drainage angle directly. Gonioscopy can help distinguish open-angle from angle-closure forms that require different management strategies.

Glaucoma affects many people worldwide. An estimate placed the number of people with glaucoma at 66 million worldwide, with at least 6.8 million people blind in both eyes from the condition. These figures cover glaucoma as a group, not POAG alone.

Up to one-half of patients with POAG are undiagnosed because confirming the disease can require monitoring over years for disease-related changes. A single visit may not establish whether POAG is present or changing.

Infographic showing three glaucoma examination and burden figures: a visual-field test takes about 10 minutes per eye, an estimated 66 million people worldwide have glaucoma, and at least 6.8 million are blind in both eyes.
A glaucoma evaluation may be brief for an individual test, while the worldwide burden remains substantial.

Why follow-up testing matters

Glaucoma progression is identified by comparing test results over time. Doctors compare optic-nerve scans and visual-field tests instead of relying on one result. Visual-field testing helps show the stage and pace of glaucoma, and optic-nerve imaging may include OCT.

Doctors need regular testing and trend-based analysis to judge how quickly glaucoma is changing. A trend means that several results are reviewed together to distinguish a lasting change from a single unusual result. This approach also helps show whether a treatment plan is keeping the disease stable.

Trend-based review is different from judging a single pressure, scan, or visual-field result in isolation. Clinicians may weigh the rate of glaucoma-related change against disease severity, life expectancy, and the daily activities a person needs to preserve when deciding whether progression is clinically important.

Central vision can remain at 20/20 in early and moderate glaucoma, and sometimes even in advanced disease, while advanced disease can severely affect side vision. A clear central-vision chart result therefore does not by itself show that the optic nerve and side vision are stable.

Most treated eyes do not progress fast enough to cause future visual impairment, but 3% to 17% of eyes remain at risk even under clinical care. The 3% to 17% range describes eyes in the progression analysis, not a prediction for your eye. Your risk depends on your findings, the rate of change, and the vision you need to preserve.

A FlowWithPanels infographic shows repeated testing, trend analysis, and vision context converging into a progression assessment. It notes that central vision may stay at 20/20 while advanced disease severely affects side vision.
Follow-up compares patterns, not just one test result.

What treatment is trying to do

POAG treatment is designed to lower eye pressure and preserve as much vision as possible. Lowering eye pressure is the treatment shown to stop or slow the progression of vision loss in POAG. Most treatments aim to lower eye pressure even when the pressure does not seem especially high.

Treatment aims to keep eye pressure in an individualized target range and keep the optic nerve and visual fields stable. A target range is not the same for every person because the target depends on the eye findings and how the disease behaves.

A target pressure is an estimated upper limit for a range in which the eye is expected to remain stable or worsen slowly enough that added treatment may not be justified. An ophthalmologist may lower the target when optic-nerve damage is more severe, glaucoma is progressing rapidly, or other risk factors are present.

The target is individualized and may change over time. The 25% figure describes an initial benchmark, not a pressure goal you should set for yourself. Your eye doctor uses your examination and test results to choose and adjust the target.

How eye drops and laser may fit

POAG treatment may lower eye pressure with eye drops, laser treatment, or surgery. Eye drops and selective laser trabeculoplasty are two approaches that may be discussed before or alongside other care.

Option How it may fit What shapes the decision
Eye drops Medical therapy is presently the most common initial way to lower eye pressure. Clinicians balance effectiveness with side effects when choosing a regimen.
Selective laser trabeculoplasty Selective laser trabeculoplasty is a first-line POAG treatment and may be used as initial or additional therapy. Eye findings, treatment goals, access, side effects, and convenience affect the discussion.

Both options require a plan for checking the response. A treatment choice is not based on the treatment name alone.

Prostaglandin eye drops often provide sustained pressure lowering and are generally well tolerated. Redness, eyelid or iris pigmentation, and eyelash growth may limit their use for some people. Possible side effects are one reason a clinician reviews the regimen instead of assuming that every pressure-lowering drop fits every person.

The choice between eye drops and laser depends on your eye findings, treatment goals, access, side effects, and convenience. Selective laser trabeculoplasty may be appropriate for some people with POAG, but it may not suit everyone. Ongoing management remains necessary after laser treatment to assess the response and watch for progression.

If eye drops are recommended, the treatment plan may change when the pressure or other test results do not reach the target. If laser is recommended, follow-up still matters because the procedure does not remove the need to monitor your disease.

A FlowWithPanels infographic shows eye drops, laser treatment, and a follow-up plan converging into an individualized treatment discussion. It states that treatment choice depends on eye findings, goals, access, side effects, and convenience.
The choice is part of a monitored treatment plan.

When surgery enters the discussion

Incisional glaucoma surgery may enter the discussion when eye pressure is extremely high, medication is not acceptable or is difficult to use consistently, or visual-field damage is significant at presentation. An eye specialist may consider surgery sooner in those circumstances.

Surgery is one pressure-lowering option among several. The decision depends on the amount of damage, the response to other treatment, and whether the treatment plan can be followed consistently. A surgical recommendation therefore follows the examination findings rather than the POAG label alone.

Some minimally invasive procedures may be considered as a frontline way to avoid medicines in selected cases. Trabeculectomy and tube procedures are examples of incisional surgery that facilitate fluid drainage. Incisional glaucoma operations can have complications and can fail over time because of scarring.

What long-term management involves

Long-term glaucoma management includes repeated checks rather than a single treatment visit. Follow-up monitoring can include eye-pressure checks, visual-field testing, and optic-nerve scans or photographs. You still need ongoing follow-up after selective laser trabeculoplasty to check your response and monitor for progression.

Follow-up frequency depends on how advanced and stable your glaucoma is. Early, stable cases may need reviews once or twice a year, while higher-risk cases need closer follow-up. Your schedule can change when test results show a different rate of change.

A stable appointment does not mean that future monitoring is unnecessary. Glaucoma can progress without obvious symptoms, so the comparison between visits remains part of the care plan.

Many patients remain stable for years or even decades after reaching a safe eye pressure, but ongoing treatment is needed to maintain that stability. Most people with glaucoma do not go blind, especially when it is diagnosed early and managed consistently. Severe vision loss is now rare in people who attend follow-up appointments and follow their treatment plan.

Your part in long-term care is practical:

  • Take your treatment as prescribed.
  • Attend follow-up visits.
  • Report concerns promptly.
  • Keep the monitoring schedule even when your central vision seems clear.

Consistent follow-up gives your eye-care team the results needed to compare pressure, visual-field, and optic-nerve findings over time.

Not following a prescribed glaucoma drug regimen can make treatment less effective and increase treatment costs. Side effects, cost, and difficulty using a regimen are information that can shape the next treatment discussion. Healthy lifestyle choices may support eye and nerve health, but they cannot replace medical treatment. Pressure-lowering treatment remains central to preventing progression.

What POAG care may cost

POAG care does not have one reliable typical price. Costs differ by the service provided, disease severity, treatment, time period, and setting measured. An evaluation may involve several tests, while ongoing care may include medication, laser treatment, surgery, or repeat monitoring. The figures below describe reported costs and model estimates, not a personal bill.

An outpatient median is not the same as a total cost of care, and a pharmacy median is not the same as the price of every medication. A 25-year model estimate combines costs across a treatment pathway and does not describe one appointment. Insurance coverage and the care setting can also change what you pay for similar services. When you ask about a price, identify whether the amount covers an examination, testing, medication, laser treatment, surgery, or follow-up. Identify whether the amount is an outpatient cost, a pharmacy cost, or a long-term model estimate. Different units and time frames cannot be compared as if they were the same bill. A lower amount for one service does not show that the full POAG treatment pathway will cost less overall. A quoted price also may exclude later monitoring.

U.S. claims data measured costs for people with open-angle glaucoma. The analysis reported median eye-related outpatient costs of $639 for severe disease, $546 for moderate disease, and $476 for mild disease. The same analysis reported median glaucoma-related pharmacy costs of $493 for severe disease, $244 for moderate disease, and $139 for mild disease.

These are median costs, meaning half of the measured costs were higher and half were lower in each group. They describe the analysis population and its measured services, not the amount you will pay for a POAG visit or treatment.

The reported outpatient interquartile ranges were $381–$1,264 for severe disease, $345–$950 for moderate disease, and $304–$765 for mild disease. The reported pharmacy interquartile ranges were $122–$1,457 for severe disease, $84–$1,113 for moderate disease, and $66–$818 for mild disease. An interquartile range describes the middle half of measured costs.

A 25-year model of newly diagnosed open-angle glaucoma predicted costs of US$2,700 without treatment, US$13,788 with laser trabeculoplasty, and US$18,101 with prostaglandin analogs. The model did not include indirect costs such as productivity. Because these were model predictions over 25 years, they should not be treated as a current annual bill or a quote for your care.

A U.S. source reported an average screening eye-examination cost of $71, with additional charges for computerized instruments. That figure describes an average reported in that source and does not establish a current price for a POAG evaluation. The amount you pay can differ according to which tests and treatments your examination requires.

The cost pattern in the claims analysis also changed with disease severity. In adjusted analyses, worsening disease was associated with at least 2-fold higher annual eye-related outpatient costs. That association does not tell you what your care will cost, but it shows why a cost question needs the diagnosis, services, treatment plan, and period of care together. The claims analysis included 177,352 ocular-hypertension and open-angle-glaucoma patients; 67.8% of those patients had open-angle glaucoma. The claims analysis found higher eye-related outpatient costs for open-angle glaucoma than for ocular hypertension.

A horizontal bar chart shows reported median U.S. glaucoma costs by severity: severe outpatient $639, moderate outpatient $546, mild outpatient $476, severe pharmacy $493, moderate pharmacy $244, and mild pharmacy $139.
Reported median outpatient and pharmacy costs varied by disease severity.

What to do first

Concern about POAG calls for a qualified eye evaluation, not a conclusion based on symptoms or one pressure reading. Arrange an examination if you have noticed gradual side-vision changes, have a relevant risk factor, or have been told that your optic nerve or eye pressure needs follow-up.

If an eye-care professional has already asked you to repeat testing, keep that follow-up even if your vision seems unchanged. Repeated measurements may be needed to document changes that a single visit cannot establish.

A practical first plan is:

  1. Write down the vision changes or eye concerns that prompted you to seek care.
  2. Mention family history and health conditions that may affect glaucoma risk.
  3. Bring the names of current eye treatments to the visit.
  4. Keep taking prescribed treatment and attend follow-up visits if you already have a glaucoma plan.
  5. Report new concerns promptly.

Do not try to diagnose or rule out POAG from symptoms or one eye-pressure reading. Do not change prescribed treatment on your own; discuss concerns with the clinician managing your care.

When to seek immediate eye care

Sudden narrowing or loss of vision requires immediate eye care. Do not wait for a routine glaucoma visit if your vision suddenly narrows or fades.

Arrange an eye examination for your next step

POAG can develop with few early symptoms, so the useful answer comes from combined testing and comparison over time. Treatment focuses on lowering eye pressure, preserving remaining vision, and adjusting care when the findings change. Northwest Eye in Minnetonka is a local setting for eye evaluation when POAG concerns are not an emergency. A qualified eye-care professional must decide what your examination means and which treatment, if any, fits your condition.

Questions about POAG diagnosis, treatment, and cost

What does POAG care typically cost, and what changes the price?

There is no reliable single price for POAG care. Your cost can change with the examination and tests, disease severity, medicines, laser or surgery, insurance, and the care setting. Reported U.S. analyses found median outpatient costs of $476 for mild, $546 for moderate, and $639 for severe open-angle glaucoma, but these are not personal quotes.

Is POAG a lifelong condition?

POAG is generally a chronic condition that requires ongoing monitoring and management rather than a short illness with a fixed end date. Glaucoma often changes over years rather than months, but the pace differs between people. Follow-up testing helps your eye doctor adjust treatment and check whether pressure, the optic nerve, and visual fields remain stable.

When should a vision change be treated as an eye emergency?

Seek immediate eye care if your vision suddenly narrows or fades. Get prompt eye-care help for eye pain or pressure, persistent redness, halos around lights, or nausea or vomiting with eye symptoms. Gradual side-vision changes usually call for a qualified eye examination, but symptoms alone cannot identify the cause or rule out POAG.


locations

Serving Our Community

With six locations throughout the Twin Cities metro area, Northwest Eye is among the largest eye care providers in the Midwest. Be Eye Wise and schedule a general eye exam or a specific service consultation today. We have optical  at the following offices:  Golden Valley, Minnetonka, Maple Grove, St. Anthony, and Wayzata, MN.

8501 Golden Valley Rd.,
Suite 100 & 200
Golden Valley, MN 55427
Additional Golden Valley Information
12501 Whitewater Drive, Suite 110
Minnetonka, MN 55343
Additional Minnetonka Clinic (Crosstown) Information
12000 Elm Creek Blvd N., Suite 100
Maple Grove, MN 55369
Additional Maple Grove Information
2601 39th Ave NE., Suite 1
St. Anthony, MN 55421
Additional St. Anthony Information
1903 E. Wayzata Blvd., Suite 110
Wayzata, MN 55391

Additional Wayzata Information
7125 Tamarack Rd, Suite 150,
Woodbury, MN 55125
Additional Woodbury Information
11091 Ulysses St NE., Suite 400
Blaine, MN 55434
Additional Blaine Surgery Center Information
9801 Dupont Ave S., Suite 100
Bloomington, MN 55431
Additional Bloomington Surgery Center Information
12501 Whitewater Drive
Suite 320
Minnetonka, MN 55343
Additional Crosstown Surgery Center Information
10709 Wayzata Blvd., Suites 100 & 120
Minnetonka, MN 55305
Additional Minnetonka Surgery Center Information